Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study

被引：74

作者：

Kumar, K. V. S. Hari ^{[1
]}

Shaikh, Altamash ^{[2
]}

Prusty, Pitambar ^{[1
]}

机构：

[1] Command Hosp, Dept Endocrinol, Lucknow 226002, Uttar Pradesh, India

[2] PD Hinduja Hosp & Med Res Ctr, Dept Endocrinol, Mumbai 400016, Maharashtra, India

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2013年 / 100卷 / 02期

关键词：

Type; 1; diabetes; GLP-1; Incretin modulators; Exenatide; Sitagliptin; THERAPY; EXCURSIONS; CELLS;

D O I：

10.1016/j.diabres.2013.01.020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：E55 / E58

页数：4

共 20 条

[1] Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes [J].

Dupré, J ;

Behme, MT ;

McDonald, TJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07) :3469-3473

[2] Making progress: preserving beta cells in type 1 diabetes [J].

Gallagher, Mary Pat ;

Goland, Robin S. ;

Greenbaum, Carla J. .

YEAR IN DIABETES AND OBESITY, 2011, 1243 :119-134

[3] Treatment of type 1 diabetes with anti-CD3 monoclonal antibody [J].

Glandt, M ;

Hagopian, W ;

Herold, KC .

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2003, 4 (04) :361-368

[4] The physiology of glucagon-like peptide 1 [J].

Holst, Jens Juul .

PHYSIOLOGICAL REVIEWS, 2007, 87 (04) :1409-1439

[5] Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients [J].

Kielgast, Urd ;

Asmar, Meena ;

Madsbad, Sten ;

Holst, Jens J. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05) :2492-2496

[6] Incretin-based therapies for type 2 diabetes mellitus [J].

Lovshin, Julie A. ;

Drucker, Daniel J. .

NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (05) :262-269

[7] NATURAL COURSE OF REMISSION IN IDDM DURING 1ST YR AFTER DIAGNOSIS [J].

MARTIN, S ;

PAWLOWSKI, B ;

GREULICH, B ;

ZIEGLER, AG ;

MANDRUPOULSEN, T ;

MAHON, J .

DIABETES CARE, 1992, 15 (01) :66-74

[8] Beta cell mass in diabetes: a realistic therapeutic target? [J].

Meier, J. J. .

DIABETOLOGIA, 2008, 51 (05) :703-713

[9] Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function [J].

Mudaliar, Sunder ;

Henry, Robert R. .

AMERICAN JOURNAL OF MEDICINE, 2010, 123 :S19-S27

[10] Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J].

Nathan, DM ;

Cleary, PA ;

Backlund, JYC ;

Genuth, SM ;

Lachin, JM ;

Orchard, TJ ;

Raskin, P ;

Zinman, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2643-2653

← 1 2 →